|2022.6.29||Dr Satoshi Funada and colleages critically reviewed how inadequate reporting of adjudicators in open-label trials of anticancer drugs is: Funada S, Luo Y, Kataoka Y, Yoshioka T, Fujita Y, Yoshida S, Katsura M, Tada M, Nishioka N, Nakamura Y & Furukawa TA (in press) Inadequate reporting of adjudicators in open-label trials of anticancer drugs: A methodological review of 155 reports between 2017 and 2021. Journal of Clinical Epidemiology (IF=7.4).|
|2022.6.24||Dr Yusuke Tsutsumi and colleagues showed that treatament-specific effects were, on average, larger for subjective outcomes than objective or semi-objective outcome: Tsutsumi Y, Tsujimoto Y, Tajika A, Omae K, Fujii T, Onishi A, Kataoka Y, Katsura M, Noma H, Sahker E, Ostinelli EG & Furukawa TA (in press) The proportion attributable to contextual effects in general medicine: A meta-epidemiological study based on cochrane reviews. BMJ Evidence-Based Medicine (IF=4.7).|
|2022.6.24||Dr Yuki Kataoka and colleagues showed how retracted papers continued to affect systematic reviews and guidelines: Kataoka Y, Tsujimoto Y, Ariie T, Taito S, Suzuki T, Oide S & Furukawa TA (in press) Retracted randomised controlled trials were cited and not corrected in systematic reviews and clinical practice guidelines. Journal of Clinical Epidemiology (IF=7.4).|
|2022.6.15||Assistant Professor LUO Yan has pointed out a need for transparent reporting the calculation methods for effect sizes (SMDs): Luo Y & Furukawa TA (in press) effect size calculation needs to be specified with details: Comment on Ying et al. Psychological Medicine (IF=10.6).|
|2022.5.26||Professor Furukawa contributed a commentary in the Lancet Psychiatry (IF=77.1) on a digitally-assisted program fo relapse prevention among people with schizophrenia: Furukawa TA & Bighelli I (2022) Digital aids for relapse prevention in schizophrenia. Lancet Psychiatry, 9, 424-425.|
|2022.5.26||Assistant Professor LUO Yan had a paper accepted in Journal of Clinical Epidemiology (IF=7.4): Luo Y, Funada S, Yoshida K, Noma H, Sahker E & Furukawa TA (in press) Large variation existed in standardized mean difference estimates using different calculation methods in randomized controlled trials.|
|2022.5.24||Yi-Husan Lin, MPH (a double degree student from National Taiwan University in 2021) had a paper accepted in eClinicalMedicine (IF=17.0), an open access journal of the Lancet group: Lin Y-H, Sahker E, Shinohara K, Horinouchi N, Ito M, Lelliot M, Cipriani A, Tomlinson A, Baethge C & Furukawa TA (in press) Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000–2020: A systematic review and meta-analysis.|
|2022.5.6.||Rie Toyomoto RN, MW, MPH (Researcher) had a paper from the Healthy Campus Trial accepted in Frontiers in Psychology (IF=4.2): Toyomoto R, sakata M, Yoshida K, Luo Y, Nakagami Y, Iwami T, Aoki S, Irie T, Sakano Y, Suga H, Sumi M, Ichikawa H, Watanabe T, Tajika A, Uwatoko T, Sahker E & Furukawa TA (in press) Validation of the Japanese Big Five Scale Short Form in a university student sample.|
|2022.5.5.||Professor Furukawa, together with Astrid Chevance, Philippe Ravaud (Université Paris Cité), Victoria Cornelius (Imperial College London) and Evan Mayo-Wilson (Indiana University), published a call for more "patient-near" RCTs of psychiatric drugs in the Lancet Psychiatry (IF=77.1): Chevance, A., P. Ravaud, V. Cornelius, E. Mayo-Wilson and T. A. Furukawa (2022). "Designing clinically useful psychopharmacological trials: challenges and ways forward."|
|2022.4.1||Asst Prof Sahker and our department members had a paper accepted in Journal of General Internal Medicine (IF=6.5): Sahker E, Luo Y, Sakata M, Toyomoto R, Hwang C, Yoshida K, Watanabe N & Furukawa TA (in press) Efficacy of brief intervention for unhealthy drug use in outpatient medical care: A systematic eview and meta-analysis|
|2022.3.28||Chiyoung Hwang, MPH (graduate of PhD course) had a paper accepted in Journal of Gambling Studies (IF=3.4): Hwang C, Takano T, So R, Sahker E, Kawakami S, Livingstone C, Takiguchi N, Ono-Kihara M, Kihara M & Furukawa TA (in press) Prevalence of gambling disorder and its correlates among homeless men in Osaka City, Japan|
|2022.3.24||Asst Prof Sakata and the team have published he primary results from the Healthy Campus Trial in Evidence-Based Mental Health (IF=13.5): Sakata M, Toyomoto R, Yoshida K, Luo Y, Nakagami Y, Uwatoko T, Shimamoto T, Tajika A, Suga H, Ito H, Sumi M, Muto T, Ito M, Ichikawa H, Ikegawa M, Shiraishi N, Watanabe T, Sahker E, Ogawa Y, Hollon SD, Collins LM, Watkins ER, Wason J, Noma H, Horikoshi M, Iwami T and Furukawa TA (in press). Components of smartphone cognitive-behavioural therapy for subthreshold depression among university students: A factorial trial.|
|2022.3.12||We are very proud to announce that our graduates continue to conduct cutting-edge research in collaboration, years after their graduation from the master or doctoral courses. Drs Hissei Imai, Nozomi Takeshima, Yu Hayasaka, in collaboration with A/Professors Aran Tajika and Yusuke Ogawa (all graduates from our department), had a paper accepted in Journal of Medical Internet Research (IF=7.1): Imai H, Tajika A, Narita H, Yoshinaga N, Kimura K, Nakamura H, Takeshima N, Hayasaka Y, Ogawa Y and Furukawa TA (in press). Unguided computer-assisted self-help interventions without human contact in patients with obsessive-compulsive disorder: A systematic review and meta-analysis.|
|2022.3.11||A/Professors Ethan Sahker and Masatsugu Sakata had a paper accepted by Drug and Alcohol Dependence (IF=4.9) : Sahker E, Pro G, Sakata M, Poudyal H, Jordan A & Furukawa TA (in press) Factors supporting substance use improvement for black americans: A population health observational study.|
|2022.2.18||Dr Kazumichi Yamamoto (visiting researcher), together with seveal members from the Department, had a validation paper on MARS accepted in Journal of Medical Internet Research (IF=7.1): Yamamoto K, Ito M, Sakata M, Koizumi S, Hashisako M, Sato M, Stoyanov SR and Furukawa TA (in press). Development and validation of a japanese version of the mobile app rating scale (MARS).|
Professor Furukawa, together with 25 leading experts in psychiatry, psychology, neurosciences, health economics, public health and people with lived exepreinces from 25 countries, has contributed to the Lancet-World Psychiatric Association Commission on Depressio: Herrman H*, Patel V*, Kieling C*, Berk M†, Buchweitz C†, Cuijpers P†, Furukawa TA†, Kessler RC†, Maj M†, McGorry P†, Reynolds III CF†, Weissman MM†, Chibanda D, Dowrick C, Howard LM, Hoven CW, Knapp M, Kohrt BA, Mayberg HS, Penninx BWJH, Shuiyuan X, Trivedi M, Uher R, Vijayakumar L and Wolpert M (in press). Time for unitedaction on depression: A lancet-world psychiatric association commission. Lancet (IF=202.7). * Contributed equally, † Lead writing group
The Lancet organized a global launch webinar for the Commission. It was a truly impressive weibinar, moderated by the Lancet Editor-in-Chief Dr Richard Horton with an impressive group of participants including the US Surgeon General Dr Vivek H. Murphy among others. You can hear them talk on: https://event.on24.com/wcc/r/3570306/508431E37714BA0389EC3F34BBE50DC
|2022.1.28||Shino Kikuchi (MD, visiting researcher) had her major work accepted in American Journal of Gastroenterology (IF=12.0): Kikuchi S, Oe Y, Ito Y, Sozu T, Sasaki Y, Sakata M, Luo Y, Sahker E, Horikoshi M, Seno H & Furukawa TA (in press) Group cognitive behavioral therapy with interoceptive exposure for drug-refractory irritable bowel syndrome: a randomized controlled trial.|
|2022.1.21||Yasushi Tsuimoto (MD, visiting researcher), A/Prof Aran Tajika and others had a paper accepted by Journal of Clinical Epidemiology (IF=7.4) :Tsujimoto Y, Fujii T, Tsutsumi Y, Kataoka Y, Tajika A, Okada Y, Carrasco-Labra A, Devji T, Wang Y, Guyatt GH & Furukawa TA (in press) Minimal important changes in standard deviation units are highly variable and no universally applicable value can be determined.|
|2022.1.1||We published 63 articles in English in 2021 (including letters but excluding those in press or online ahead of print), of which 20 (31.7%) were in journals with IF greater than 10.|
|2021.11.17||Prof Furukawa was nominated "2021 Highly Cited Researcher" by Clarivate/Web of Science. The Highly Cited Researchers™ list from Clarivate™ identifies scientists who have demonstrated significant influence through publication of multiple highly cited papers during the last decade. All Highly Cited Researcher records are reviewed. Factors such as retractions, misconduct, and extreme self-citation—all of which would detract from true community-wide research influence—may lead to an author being excluded from the list. Approximately 6,600 researchers are named Highly Cited Researchers in 2021, or about 0.1% of the scientists in the world. Prof Furukawa is the only Highly Cited Researcher from Kyoto University Graduate School of Medicine this year.|
|2021.10.26||Ms Rie Toyomoto (3rd year PhD candidate), together with Dr Satoshi Funada (4th year PhD candidate), has the following Letter to the Editor accepted in JAMA Psychiatry (IF=21.6): Toyomoto R, Funada S & Furukawa TA (in press) Some concerns about imputation methods for missing data.|
|2021.10.26||One more great German-Italo-Sino-Japanese (plus some more perhaps) collaboration elucidating the importance of psychosocial interventions for people with schizophrenia to be published in Lancet Psychiatry (IF=26.5) : Rodolico A, Bighelli I, Avanzato C, Concerto C, Cuutrufelli P, Mineo L, Schneider-Thoma J, Siafis S, Signorelli MS, Wu H, Wang D, Furukawa TA, Pitschel-Walz G, Aguglia E & Leucht S (in press) Family interventions for relapse prevention in schizophrenia: systematic review and network meta-analysis. Lancet Psychiatry.|
|2021.9.9||The network meta-analysis contributed by many members in the Department is now published in World Psychiatry (IF=49.5): Furukawa TA, Shinohara K, Sahker E, Karyotaki E, Miguel C, Ciharova M, Bockting CL, Breedvelt JF, Tajika A, Imai H, Ostinelli EG, Sakata M, Toyomoto R, Kishimoto S, Ito M, Furukawa Y, Cipriani A, Hollon SD & Cuijpers P (2021) Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. 20, 387-396.|
|2021.8.28||Dr Morihiro Katsura, together with many members from the Department, has had the following meta-epidemiological study on redundant systematic reviews accepted by British Journal of Surgery (IF=6.9): Katsura M, Kuriyama A, Tada M, Tsujimoto Y, Luo Y, Yamamoto K, So R, Aga M, Matsuhima K, Fukuma S & Furukawa TA (in press) High variability in results and methodological quality among overlapping systematic reviews on the same topics in surgery: a meta-epidemiological investigation.|
|2021.8.26||Dr Yasushi Tsujimoto's very interesting research on the review methodology has been accepted by Journal of Clinical Epidemiology (IF=6.4): Tsujimoto Y, Tsutsumi Y, Kataoka Y, Banno M & Furukawa TA (in press) Around ten percent of most recent Cochrane reviews included outcomes in their literature search strategy and were associated with potentially exaggerated results: A research-on-research study.|
臨床研究に興味のある医師の皆さまのご参加をお待ちしています。 詳しくは こちらをご覧ください。
|2019.7.19||Another fantasitic contribution to the more balanced treatments of people with schizophrenia from the great German-Italo-Greco-Chinese-Japanese collaboration, to be published in Lancet Psychaitry (IF=27.1): Bighelli I, Rodolico A, Garcia-Mieres H, Pitschel-Walz G, W.-P. H, Schneider-Thoma J, Siafis S, Wu H, Wang D, Salanti G, Furukawa TA, Barbui C & Leucht S (in press) Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.|
|2021.7.19||The great German-UK-US-Italo-Greco-Japanese collaboration led to this fantastic primer on how to interpret continuous outcomes in clinical trials, to be published in Schizophrenia Bulletin (IF=9.3): Leucht S, Siafis S, Mavridis D, Engel RR, Schneider-Thoma J, Bighelli I, Cipriani A, Furukawa TA & Davis JM (in press) How efficacious are antipsychotic drugs for schizophrenia? an interpretation based on 13 effect size indices.|
|2021.6.4||Professor Furukawa co-authored a paper on the clinimetric principle for patient-reported outcomes, published ahead of print in Psychotherapy and Psychosomatics (IF=14.9): Carrozzino D, Patierno C, Guidi J, Berrocal Montiel C, Cao J, Charlson ME, Christensen KS, Concato J, De Las Cuevas C, de Leon J, Eöry A, Fleck MP, Furukawa TA, Horwitz RI, Nierenberg AA, Rafanelli C, Wang H, Wise TN, Sonino N & Fava GA (2021) Clinimetric criteria for patient-reported outcome measures. Psychotherapy and Psychosomatics.|
|2021.6.4||Drs Satoshi Funada and Luo Yan's letter to the editor was published in Lancet Oncology (IF=33.8): Funada S, Luo Y (2021) Adjuvant immunotherapy in muscle-invasive urothelial carcinoma.|
|2021.5.18||The internatioanal group of researchers led by Prof Pim Cuijpers at VU Amsterdam published the most up-to-date coprehensive review of psychotherapies for depression in World Psychiatry (IF=40.6): Cuijpers P, Quero S, Noma H, Ciharova M, Miguel C, Karyotaki E, Cipriani A, Cristea I & Furukawa TA (2021) Psychotherapies for depression: A network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. 20, 283-293.|
|2021.5.15||Drs Satoshi Funada and Luo Yan's letter to the editor was published in JAMA Oncology (IF=24.8): Funada S, Luo Y & Furukawa TA (2021) Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. https://www.ncbi.nlm.nih.gov/pubmed/33983384|
|2021.5.15||Dr Satoshi Funada's protocol paper for a prediction model study was accepted in BMC Urology: Funada S, Luo Y, Yoshioka T, Setoh K, Tabara Y, Negoro H, Akamatsu S, Yoshimura K, Matsuda F, Furukawa TA, Efthimiou O & Ogawa O (2021) Protocol for development and validation of a prediction model for 5-year risk of incident overactive bladder in the general population: the Nagahama study. BMC Urology, 21.|
|2021.3.17||Dr Kiyomi Shonohara's collaboration with a PhD candidate at the University of Oxford while she was there resulted in a publicaiton in Bipolar Disorder (IF=5.4): Xu N, Shinohara K, Saunders KEA, Geddes JR & Cipriani A (2021) Effect of lithium on circadian rhythm in bipolar disorder: A systematic review and meta-analysis.|
|2021.2.23||Dr Aya Suganuma, Dr Edoardo Ostinelli and Prof Furukawa are joint first authors for the recently accepted paper in Lancet Psychaitry (IF=16.2): Furukawa TA*, Suganuma A*, Ostinelli EG* et al (in press) Dismantling, optimising and personalising internet cognitive-behavioural therapy for depression: A systematic review and individual participant data component network meta-analysis. [* equal contribution]|
|2021.2.18||Prof Furukawa and colleagues published a meta-analytical study examining possibilities for individualized treatment rules in antidepressant therapies for depression in JAMA Psychiatry (IF=17.5): Maslej MM, Furukawa TA, Cipriani A, Andrews PW, Sanches M, Tomlinson A, Volkmann C, McCutcheon RA, Howes O, Guo X & Mulsant BH (2021) Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials.|
|2021.2.11||Drs Tsujimoto, Kataoka and many others have been conducting a workshop for developing systematic review protocols, inspired by Prof Furukawa's course on systematic revieews at KUSPH. What an honor to see such consequences to your lectures! They recently reported on their activities here: Tsujimoto H, Kataoka Y, Sato Y, Banno M, Tsujino-Tsujimoto E, Sumi Y, Sada R, Fujiwara T, Ohtake Y, Kumasawa J, Imura H, Matsuda Y, So R, Kagawa T, Yoshioka T, Uneno Y, Nagano H, Akazawa M, Hozumi T & Tsujimoto Y (2021) A model six-month workshop for developing systematic review protocols at teaching hospitals: action research and scholarly productivity. BMC Medical Education, 21, 98.|
|2021.2.1||Prof Furukawa's paper linking PHQ-9 scores into QALY values has been accepted in Evidence-Based Mental Health: Furukawa TA, Levine SZ, Buntrock C, Ebert DD, Gilbody S, Brabyn S, Kessler D, Björkelund C, Eriksson M, Kleiboer A, van Straten A, Riper H, Montero-Marin J, Garcia-Campayo J, Philips R, Schneider J, Cuijpers P & Karyotaki E (in press) How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis of PHQ-9 and EQ-5D
A typical acute-phase treatment with antidepressant or psychotherapy can lead to 0.05 to 0.09 QALY gain over a year, and would be worth 2,500 to 4,500 dollars.
|2021.1.14||Dr Satoshi Funada (3rd year, PhD candidate) has been awarded the KDDI Foundation scholarship for the topic, "Building an Overactive Bladder Prediction Model Using a Web Application".|
|2021.1.1||We published 48 articles in English in 2020 (excluding those in press or online ahead of print), of which nine (18.8%) were in journals with IF greater than 10.|
Prof Furukawa's co-authored paper (Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR & Cipriani A (2020) Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry.) was listed as one of the Brain and Behavior Research Foundation’s (formerly NARSAD’s) top ten research discoveries of 2020. See here.
Dr Yan LUO (3rd year, PhD) has the third of her series of EBM implementation study accepted by Journal of Clinical Epidemiology (IF=5.0): Luo Y, Ostinelli EG, Sahker E, Chaimani A, Kataoka Y, Ogawa Y, Cipriani A, Salanti G & Furukawa TA (in press) Antidepressant prescriptions have not fully reflected evolving evidence from cumulative network meta-analyses and guideline recommendations.
Prof Yannis Michopoulous (U of Athens), who stayed with us in the summer 2019, has the following paper accepted in Journal of Clinical Epidemiology (IF=5.0) with several members from the Department: Michopoulos I, Furukawa TA, Noma H, Kishimoto S, Onishi A, Ostinelli EG, Ciharova M, Miguel C, Karyotaki E & Cuijpers P (in press) Different control conditions can produce different effect estimates in psychotherapy trials for depression.
|2020.12.1||The second paper from the Healthy Campus Trial by Mr Masatsugu Sakata has been accepted in Evidence-Based Mental Health. Sakata M, Toyomoto R, Yoshida K, Luo Y, Nakagami Y, Aoki S, Irie T, Sakano Y, Suga H, Sumi M, Muto T, Shiraishi N, Sahker E, Uwatoko T & Furukawa TA (in press) Development and validation of the cognitive behavioral therapy skills scale among college students.|
|2020.11.24||A new meta-analyis of psychotherapies to prevent depression was accepted in Clinical Psychology Review (IF=10.3). Cuijpers P, Pineda BS, Quero S, Karyotaki E, Struijs SY, Figueroa CA, Llamas JA, Furukawa TA & Munoz RF (in press) Psychological interventions to prevent the onset of depressive disorders: A meta-analysis of randomized controlled trials.|
|2020.11.1||Dr Ryuhei So (Visiting Researcher, Graduate from MCR) was awarded the best presentation award at the 116th Annual Meeting of the Japanese Society of Neurology and Psychiatry for his presentation "Unguided Chatbot-delivered Intervention for Problem Gamblers: An Online Randomized Controlled Trial."|
|2020.9.15||The protocol for the systematic review and meta-analysis of brief interventions led by Prof Sahkler has been published in BMJ Open: Sahker E, Sakata M, Toyomoto R, Hwang C, Yoshida K, Luo Y, Watanabe N & Furukawa TA (2020) Efficacy of brief intervention for drug misuse in primary care facilities: systematic review and meta-analysis protocol, 10, e036633.|
|2020.9.11||Dr Satoshi Funada and Dr Luo Yan had a letter to the editor accepted in JAMA Internal Medicine (IF=18.7) Comments from clinicians on implementing group-based pelvic floor muscle training in clinical practice [Letter to the editor].|
|2020.9.7||Dr Kazufumi Yoshida (2nd year, DrPH) had a joint-first-authored paper accepted in Evidence-Based Mental Health: Levine SZ*, Yoshida K*, Goldberg Y, Cipriani A, Efthimiou O, Iwatsubo T, Leucht S & Furukawa TA (in press) Linking the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, and the Severe Impairment Battery: Evidence from individual participant data from five randomized clinical trials of donepezil. (*: equal contribution). This is the first of a series of studies to come out of the donepezil trial IPD database.|
|2020.8.25||Dr Shino Kikuchi (4th year, PhD) published a full Cochrane review (IF=7.9) : Kikuchi S, Imai H, Tani Y, Tajiri T & Watanabe N (2020) Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews.|
|2020.8.13||The protocol paper for the randomized controlled trial by Dr Satoshi Funada (3rd year, PhD) was accepted in BMC Urology (IF=1.6): Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Ueno K, Uozumi R, Ichioka K, Segawa T, Akechi T, Furukawa TA & Ogawa O (in press) Cognitive-behavioral therapy for overactive bladder in women: Study protocol for a randomized controlled trial.|
|2020.8.13||Dr Satoshi Funada (3rd year, PhD) and Dr Yan Luo's (3rd year, PhD) letter to the editor was accepted by European Urology (IF=17.6): Funada S, Yoshioka T & Luo Y (in press) Re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Published: July 11, 2020.|
|2020.8.7||Dr Ryuhei So and Dr Shino Kikuchi were awarded a continuing research grant from Mental Health Okamoto Foundation.|
|2020.7.30||Prof Furukawa, together with Prof David Miklowitz (UCLA), Prof Andrea Cipriani (U of Oxford) among others, had a component network meta-analysis of psychotherapies for bipolar disorder accepted in JAMA Psychaitry (IF=17.5): Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR & Cipriani A (in press) Adjunctive psychotherapies for bipolar disorder: A systematic review and network meta-analysis.|
|2020.7.3||Drs Aran Tajika, Kiyomi Shinohara and Hissei Imai's systematic review and meta-analysis of antidepressant maintenance therapy in major depression was accepted in Molecular Psychiatry (IF=12.4) : Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, Shinohara K, Imai H, Murata A, Mishima K & Tajika A (in press) Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: A systematic review and meta-analysis.|
|2020.6.25||Dr Yan Luo and Dr Satoshi Funada's letter to the editor was accepted by Arthritis & Rheumatology (IF=9.0): Luo Y, Funada S, Yoshioka T & Furukawa TA (in press) Challenges in systematic reviews including observational studies.|
|2020.6.22||Dr Satoshi Funada (3rd year, PhD) and Dr Yan Luo's (3rd year, PhD) letter to the editor was accepted by European Urology (IF=17.6): Funada S, Yoshioka T & Luo Y (in press) Re: Moris L, Cumberbatch MG, Van den Broeck T. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. 2020: 77(5):614-627.|
|2020.6.5||Prof Furukawa, together with Prof Gordon Guyatt's team at McMaster Universtiy in Canada, has published a framework to assess creditibiity of Minimal Important Change derived from anchor-based studies in BMJ (IF=27.6): Devji T, Carrasco-Labra A, Qasim A, Phillips M, Johnston BC, Patrick DL, Ebrahim S, Furukawa TA, Nesrallah G, Schunemann HJ, Bhandari M, Thabane L & Guyatt GH (in press) Development and inter-rater reliability of an instrument to evaluate the credibility of anchor-based minimally important difference estimates for patient reported outcome measures. Open Access|
|2020.5.28||Dr Yan Luo (3rd year, PhD)'s protocol paper for a new IPD-MA was accepted in Systematic Reviews: Luo Y, Chalkou K, Yamada R, Funada S, Salanti G & Furukawa TA (in press) Predicting the treatment response of certolizumab for inidividual adult patient with rheumatoid arthritis: Protocol for an individual participant data meta-analysis.|
|2020.5.21||Dr Yan Luo (3rd year, PhD) was awarded "EBMLive 2020 David L. Sackett Fellowship" for her proposed presentation "Visualizing the Evolution of Evidence: Cumulative Network Meta-Analyses of New Generation Antidepressants in the Last 40 Years." She will be invited to join the meeting in Oxford 12-14 July for EBMLive 2021.|
|2020.5.19||Dr Satoshi Funada (3rd year, PhD) has had another paper accepted. This time in LUTS: Lower Urinary Tract Symptoms (IF=1.0): Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Uozumi R, Kishimoto S, Ichioka K, Segawa T, Furukawa TA & Ogawa O (in press) Clinical feasibility and acceptability of adding cognitive behavioral therapy to pharmacotherapy for drug-resistant overactive bladder in women: a single-arm pilot study.|
|2020.5.11||Dr Satoshi Funada (3rd year, PhD)'s paper was accepted in Journal of Urology (IF=5.6): Funada S, Tabara Y, Setoh K, Negoro H, Akamatsu S, Yoshino T, Yoshimura K, Watanabe N, Furukawa TA, Matsuda F, Ogawa O & Nagahama Study Group (in press) Impact of nocturia on mortality: the Nagahama Study.|
|2020.4.29||Professor Furukawa was featured in Profile in this month's Lancet Psychiatry (IF=18.3). He was interviewed about his life and works. Prof Furukawa states, "It was a real surprise and a huge honor to be contacted for this interview. The interview made me realize once again how much I owe to my teachers, colleagues, friends and students. I hope this will give me a new impetus for the next round of research." Please read the full article at https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30157-7/fulltext.|
Dr Yan Luo (3rd year, PhD)'s paper was accepted in Research Syntheis Methods (IF=5.0). Luo Y, Chaimani A, Furukawa TA, Kataoka Y, Ogawa Y, Cipriani A & Salanti G (in press) Visualizing the evolution of evidence: Cumulative network meta-analyses of new generation antidepressants in the last 40 years.
Please see the beautiful interactive presentations of cumulative network meta-analyses in R Shiny at https://cinema.ispm.unibe.ch/shinies/GRISELDA/.
|2020.4.8||Dr Saori Goto from the Department of Gastrointestinal Surgery has had her Cochrane systematic review accepted (IF=7.8): Goto S, Sakamoto T, Ganeko R, Hida K, Furukawa TA & Sakai Y (2020) Subcuticular sutures for skin closure in non-obstetric surgery. Cochrane Database of Systematic Reviews, Art. No.: CD012124. She was former student of Prof Furukawa in his systematic review course in 2014: and this reivew is a fruit of her six years of persistent and indefatiguable efforts.|
-- COVID-19 & clinical management of mental health issues by Oxford Precision Psychiatry Lab
-- New Webinar Series: Mental Health & COVID-19 by The Lancet Psychiatry, Mental Health Innovation Network, MHPSS.net and United for Global Mental Health
|2020.3.24||Due to the COVID-19 pandemic, the open campus for 2021 will be held remotely via web (individual consultation also available). For details, please see our KUSPH homepage.|
|2020.3.20||Prof Furukawa's commentary on Bondar et al's re-analysis of TADS study appeared in this month's Lancet Psychiatry: Furukawa TA (2020) Adolescent depression: from symptoms to individualised treatment? 7, 295-296.|
|2020.3.17||A network meta-analysis of several attention bias modification interventions for depression and anxiety found one of them may be hopeful: Fodor LA, Georgescu R, Cuijpers P, Szamoskozi S, David D, Furukawa TA & Cristea IA (in press) The effectiveness of cognitive bias modification interventions in anxiety and depressive disorders: a network meta-analysis. Lancet Psychiatry. (IF=18.3)|
|2020.3.15||A letter to the editor by Dr Hissei Imai (Visiting Researcher) on the lessons learnt from the H1N1 pandemic in Japan was published online in Psychiatry and Clinical Neurosciences: Trust is a key factor in the willingness of health professionals to work during the COVID-19 outbreak: Experience from the H1N1 pandemic in Japan 2009. https://onlinelibrary.wiley.com/doi/full/10.1111/pcn.12995|
Three papers by Prof Furukawa were rated as Hot Papers (top 0.1% of the field in the past 2 years)
-- Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M & Salanti G (2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry, 6, 601-609.
-- Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA & Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391, 1357-1366.
-- Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, Hazlewood GS, Alhazzani W, Mustafa RA, Murad MH, Puhan MA, Schunemann HJ & Guyatt GH (2018) Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. Journal of Clinical Epidemiology, 93, 36-44.
and further five papers as Highly Cite Papers (top 1% of the field in that year) in the Web of Science.
|2020.3.1||Dr Shino Kikuchi's protocol paper for the ongoing randomized controlled trial of CBT for irritable bowel syndrome was published in BMC Gastroenterology (IF=2.3) : Kikuchi S, Oe Y, Sasaki Y, Ishii H, Ito Y, Horikoshi M, Sozu T, Seno H & Furukawa TA (2020) Group cognitive behavioural therapy (GCBT) versus treatment as usual (TAU) in the treatment of irritable bowel syndrome (IBS): a study protocol for a randomized controlled trial. BMC Gastroenterology, 20, 29. https://www.ncbi.nlm.nih.gov/pubmed/32019509|
|2020.3.1||A narrative review on persistent depressive disorder has been accepted in Lancet Psychiatry (IF=18.3): Schramm E, Klein DN, Elsaesser M, Furukawa TA & Domschke K (in press) Review of dysthymia and persistent depressive disorder: History, correlates and clinical implications.|
|2020.2.27||Dr. Naotsugu Iwakami (graduate from DrPH course in 2018 and currently visiting researcher) published in Journal of Clinical Epidemiology (IF=4.7): Iwakami N, Nagai T, Furukawa TA, Tajika A, Onishi A, Nishimura K, Ogata S, Nakai M, Takegami M, Nakano H, Kawasaki Y, Alba AC, Guyatt GH, Shiraishi Y, Kohsaka S, Kohno T, Goda A, Mizuno A, Yoshikawa T & Anzai T (2020) Optimal sampling in derivation studies was associated with improved discrimination in external validation for heart failure prognostic models. 121, 71-80.|
|2020.2.6||Prof Furukawa's letter to the editor appeared in JAMA (IF=51.3), reminding the difference between the MIC (Minimal Imprtant Change) and the SWD (Smallest Worthwhile Difference). We should not directly appraise the SWD, the smallest difference in response between two treatments to choose one over the other, based on the MIC, the minimal change on a specific scale that the patient would find important. The SWD is treatments-specific, while the MIC is scale-specific. Furukawa TA (2020) Measuring Clinical Importance in a Trial of Interventions for Mixed Urinary Incontinence. JAMA, 323, 479.|
|2020.1.13||Dr Yan Luo (PhD candidate, 2nd year) had a paper accepted by Frontiers in Psychiatry (IF=3.2): Luo Y, Kataoka Y, Ostinelli EG, Cipriani A & Furukawa TA (in press) National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015.|
|2020.1.9||A new and comprehensive network meta-analysis comparing psychotherapy, pharmacotherapy and their combination by Prof Cuijpers, Dr Karyotaki and Dr Vinkers (VU Amsterdam), A/Prof Noma (Institute of Statistical Mathematics), Prof Cipriani (U of Oxford) and Prof Furukawa was published in World Psychiatry (IF=34.0). Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A & Furukawa TA (2020) A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. 19, 92-107.|
We have listed our publications in 2019.
Of the 51 publicatioins in English, 15 (29.4%) were in jounals with IF greater than 5, of which 11 (21.2%) were in journals with IF greater than 10.
Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health
Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501 JAPAN